CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)

N/A

Report date: 2024/04/10 20:04:22

Base Information

Drug NameCD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology)
Drug Alias NameCD19-BAFF CAR-T Cells Therapy(YaKe Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-cell activating factor receptor modulators
TargetsB-lymphocyte antigen CD19B-cell activating factor receptor
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A